Woodford, Malin put $50m into Kymab
This article was originally published in Scrip
Cambridge, UK-based Kymab has raised $50m to complete a total $90m series B financing round which will allow the firm to further its drug discovery platform, Kymouse. Kymab, founded in 2009, has now raised a total of $120m in equity financing. The $50m is being invested by Woodford Patient Capital Trust and Malin. It follows on from $40m invested by the Wellcome Trust and the Bill and Melinda Gates Foundation earlier in the series B round.
You may also be interested in...
Sanofi’s general medicines business will embrace an omnichannel commercial model in 2022 to reduce inefficiencies and stabilize topline growth. Virtual sales reps are on the rise after a tough couple of years managing product promotion and launches online only.
The Scrip 100 universe gathers FY 2020 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales.
Uwe Schoenbeck, CSO of external science and innovation at Pfizer, knows the company set itself a high bar during the COVID-19 pandemic after rapidly bringing a breakthrough vaccine to market. While the circumstances for the development of Comirnaty were truly unique, Pfizer does not expect to rest on its laurels when it comes to innovative R&D.